NHS patients to be given experimental coronavirus therapy remdesivir


The results with remdesivir are an update from the 1,063-patient ACCT-1 trial that catapulted remdesivir to the forefront of drug candidates to treat COVID-19, and underpinned emergency use authorisation in the US.

He has been criticised for taking the drug in a bid to ward off the virus, with the World Health Organisation having stopped trialling the treatment over fears it could cause more deaths in COVID-19 patients.

Produced by the California-based company, Remdesivir has been approved under the UK's Early Access to Medicines Scheme (EAMS) after the Medicines and Healthcare products Regulatory Agency (MHRA) gave its go-ahead for NHS doctors to use the drug on patients who are seriously ill with the disease.

United Kingdom regulators say there is enough evidence to approve its use in selected Covid-19 hospital patients.

Remdesivir, the antiviral under clinical trials for treatment against novel coronavirus infection, is superior to the standard of care given to COVID-19 patients, according to a new study.

"The latest, expert scientific advice is at the heart of every decision we make, and we will continue to monitor remdesivir's success in clinical trials across the country to ensure the best results for United Kingdom patients".

So far in the United Kingdom over 36,000 people have died from the virus and a major trial could help curb the outbreak. He also said that, although more developments are needed to improve its effectiveness, Remdesivir could act as a basis for more efficient COVID-19 treatments in the future.

Montreal Canadiens part of National Hockey League playoff plans
Winnipeg sniper Patrik Laine said earlier Friday before the announcement that getting back on the ice is what matters. There are some details that still need to be hammered out to make this happen.

The teenager woke up from his coma and is now on his way back to being fully healthy.

As the numbers of Covid-19 cases and related deaths continue to rise, newly released data on Gilead's remdesivir safety and efficacy shows patients with Covid-19 who took the drug recovered faster than patients who did not take the drug.

Professor Martin Landray from the University of Oxford said: "There's a lot of interest in convalescent plasma essentially, think of it as a sort of antibody transplant, if you like".

Other experts have also said that it is the "most promising drug on offer at the moment".

Dr Stephen Griffin from the University of Leeds Medical School, said it was perhaps the most promising anti-viral for coronavirus so far.

The study was unable to confirm a benefit of either drug, used either alone or in combination with macrolide antibiotics, for patients with COVID-19, and found that their use was linked to an increased risk of serious heart rhythm complications and a decrease in in-hospital survival. It has shown promise in the past.